{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:16:50Z","timestamp":1753877810748,"version":"3.41.2"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To explore the relationship between Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Axial Spondyloarthritis Disease Activity Score (ASDAS) used in clinical practice and the Assessment of SpondyloArthritis international Society 40% (ASAS40) response, the primary endpoint in clinical trials in axial spondyloarthritis (axSpA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data from COAST-V, a phase 3 trial of ixekizumab vs placebo in biologic-na\u00efve radiographic axSpA (r-axSpA) patients, were analysed. Patients treated with ixekizumab every 4\u2009weeks were categorized using the ASAS40 response at week 16 and 52. The association between BASDAI and ASDAS disease states, respectively, and ASAS40 response achieved\/not achieved was investigated. Additionally, back pain, fatigue, Bath Ankylosing Spondylitis Functional Index, ASAS Health Index and 36-item Short Form Health Survey Physical Component Summary scores corresponding to these states were assessed. Results were reported descriptively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After 16\u2009 weeks, 48.1% (39\/81) of patients achieved an ASAS40 response. Among them, 71.8% (n\u2009=\u200928) and 43.6% (n\u2009=\u200917) achieved BASDAI &amp;lt;3 and BASDAI &amp;lt;2, respectively; 76.9% (n\u2009=\u200930) and 33.3% (n\u2009=\u200913) attained ASDAS &amp;lt;2.1 and ASDAS &amp;lt;1.3, respectively. Among ASAS40 responders at week 52 [53.1% (43\/81)], 83.8% (n\u2009=\u200936) and 51.2% (n\u2009=\u200922) of patients achieved BASDAI &amp;lt;3 and BASDAI &amp;lt;2, respectively; 93.1% (n\u2009=\u200940) and 41.9% (n\u2009=\u200918) attained ASDAS &amp;lt;2.1 and ASDAS &amp;lt;1.3. Lower BASDAI and ASDAS disease states corresponded well with less back pain, fatigue and functioning impairment and better health-related quality of life.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>More than 70% of biologic-na\u00efve r-axSpA patients who achieved an ASAS40 response, also attained low disease activity or inactive disease as measured by the BASDAI or ASDAS. Findings may help clinicians translate results from clinical trials into daily practice.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rap\/rkaf012","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T17:14:53Z","timestamp":1738170893000},"source":"Crossref","is-referenced-by-count":0,"title":["BASDAI and ASDAS disease states in relationship to ASAS40 response: post hoc analysis of ixekizumab in radiographic axial spondyloarthritis"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5445-548X","authenticated-orcid":false,"given":"Martin","family":"Rudwaleit","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Klinikum Bielefeld, Medical School and University Center OWL, Bielefeld University , Bielefeld,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4527-852X","authenticated-orcid":false,"given":"Victoria","family":"Navarro-Comp\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital La Paz, IdiPAZ , Madrid,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagen","family":"Russ","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Panni","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Filippi","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mani Haschemi","family":"Nassab","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soyi","family":"Liu-Leage","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Go\u00ebb","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Centre Hospitalier Universitaire Amiens-Picardie, UPJV , Amiens,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9352-1264","authenticated-orcid":false,"given":"Francesco","family":"Ciccia","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Palermo , Sicily,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8533-5800","authenticated-orcid":false,"given":"Jean","family":"Dudler","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, H\u00f4pital Fribourgeois , Fribourg,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"2025052701321120700_rkaf012-B1","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1136\/annrheumdis-2021-221035","article-title":"Axial spondyloarthritis","volume":"80","author":"Navarro-Comp\u00e1n","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025052701321120700_rkaf012-B2","first-page":"4","article-title":"The burden of ankylosing spondylitis","volume":"78","author":"Boonen","year":"2006","journal-title":"J Rheumatol Suppl"},{"key":"2025052701321120700_rkaf012-B3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025052701321120700_rkaf012-B4","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1136\/annrheumdis-2014-205178","article-title":"Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2025052701321120700_rkaf012-B5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025052701321120700_rkaf012-B6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11926-015-0522-3","article-title":"Clinical tools to assess and monitor spondyloarthritis","volume":"17","author":"Landew\u00e9","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"2025052701321120700_rkaf012-B7","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2025052701321120700_rkaf012-B8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2025052701321120700_rkaf012-B9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2025052701321120700_rkaf012-B10","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/ard.2003.016717","article-title":"Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis","volume":"63","author":"Brandt","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"2025052701321120700_rkaf012-B11","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","article-title":"Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"2025052701321120700_rkaf012-B12","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","article-title":"Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)","volume":"79","author":"Dougados","year":"2020","journal-title":"Ann Rheum Dis"},{"author":"US Food and Drug Administration","key":"2025052701321120700_rkaf012-B13"},{"year":"2020","author":"European Medicines Agency","key":"2025052701321120700_rkaf012-B14"},{"key":"2025052701321120700_rkaf012-B15","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/rheumatology\/ker194","article-title":"Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years\u2014early clinical response predicts long-term outcome","volume":"50","author":"Baraliakos","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"2025052701321120700_rkaf012-B16","doi-asserted-by":"crossref","first-page":"1759720X221090310","DOI":"10.1177\/1759720X221090310","article-title":"Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study","volume":"14","author":"Ramonda","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025052701321120700_rkaf012-B17","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/annrheumdis-2018-213184","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states","volume":"77","author":"Machado","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025052701321120700_rkaf012-B18","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/rheumatology\/keab494","article-title":"BASDAI cut-off values corresponding to ASDAS cut-off values","volume":"61","author":"Kwon","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025052701321120700_rkaf012-B19","doi-asserted-by":"crossref","first-page":"856654","DOI":"10.3389\/fmed.2022.856654","article-title":"The BASDAI cut-off for disease activity corresponding to the ASDAS scores in a Taiwanese cohort of ankylosing spondylitis","volume":"9","author":"Chen","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2025052701321120700_rkaf012-B20","first-page":"1163","article-title":"Equivalent cut-off values of Bath Ankylosing Spondylitis Disease Activity Index corresponding to Ankylosing Spondylitis Disease Activity Score cut-off values","volume":"41","author":"Cui","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"2025052701321120700_rkaf012-B21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3899\/jrheum.210471","article-title":"Spinal radiographic progression and predictors of progression in patients with radiographic axial spondyloarthritis receiving ixekizumab over 2 years","volume":"49","author":"van der Heijde","year":"2022","journal-title":"J Rheumatol"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkaf012\/61683662\/rkaf012.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/9\/2\/rkaf012\/61683662\/rkaf012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/9\/2\/rkaf012\/61683662\/rkaf012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T05:32:20Z","timestamp":1748323940000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkaf012\/7989308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3,14]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkaf012","relation":{},"ISSN":["2514-1775"],"issn-type":[{"type":"electronic","value":"2514-1775"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"rkaf012"}}